ICH E6(R3) is the international Good Clinical Practice (GCP) guideline for clinical trials, and FDA issued it as final guidance in September 2025. This page is for independent research sites, site networks and provider practices adding clinical research that need a site quality system built to it. Integral Healthcare Solutions (IHS) builds your site's SOP system and audit evidence to ICH E6(R3); your investigators own trial conduct and participant safety.
Last reviewed: October 2026.
What is ICH E6(R3)?
The governing text is ICH's Guideline for Good Clinical Practice E6(R3), whose final version ICH adopted on 6 January 2025. It has two layers: the Principles, and Annex 1, which expands on them. ICH notes that further annexes may be developed later. Under E6(R3), GCP is the international standard that trials with human participants are planned and run to, covering ethics, science and the quality of the work (ICH E6(R3), Introduction, document opened October 3, 2026).
E6(R3) is aimed at interventional trials of investigational products whose results are meant for regulators. ICH adds that the Principles can also be useful for other interventional trials of investigational products that are not meant to support a marketing application, as local requirements allow. It favors a risk-based approach scaled to the trial rather than one fixed method (ICH E6(R3), document opened October 3, 2026).
FDA lists the guidance as E6(R3) Good Clinical Practice (GCP), final, issued September 2025 under docket FDA-2023-D-1955. FDA says this revision adds flexible, risk-based approaches and makes room for newer trial designs and technology (FDA guidance page, page opened October 3, 2026).
For a US site running FDA-regulated drug or biologic studies, FDA's regulations also apply. 21 CFR Part 312 sets investigator commitments and records; for example, a sponsor "shall select only investigators qualified by training and experience as appropriate experts to investigate the drug" (21 CFR 312.53(a)). IHS's reading (October 2026): E6(R3) is guidance, and the enforceable requirements for a US drug or biologic site sit in FDA's regulations, such as Part 312. Confirm how that applies to your studies with your regulatory counsel.
Who needs it and what triggers it
The buyer is an independent research site, a site network, or a provider organization adding clinical research to its practice. The usual triggers:
- FDA finalized its E6(R3) guidance in September 2025 (FDA), so SOPs written before then need a check against it.
- The site is taking on interventional trials of investigational products that are meant for regulators, which is the guideline's core scope (the Principles may also help on other interventional trials).
- Sponsors are qualifying the site. Sponsors must select investigators "qualified by training and experience" (21 CFR 312.53(a)); training and delegation records are the evidence IHS recommends a site keep to support that.
- An audit or inspection is coming. Section 2.3.5 of E6(R3) is about access for outside reviewers: regulators who inspect, IRB/IEC reviewers where requirements apply, and the sponsor's monitors and auditors.
- The site uses vendors or delegates work to new staff, which brings in the delegation and service-provider sections described below.
How IHS helps
IHS builds the site's quality system through its standard process:
- A gap assessment of your current SOPs against the E6(R3) principles and annexes and the applicable 21 CFR provisions.
- Questionnaires on your studies, staff, delegation and vendors, used to build a crosswalk from each guidance expectation to an SOP and a record.
- Drafting of the site SOP system, delegation-of-authority logs, training records, vendor oversight procedures and audit-readiness procedures, for your principal investigators and site leadership to review and approve.
- A mock sponsor audit of the assembled system, read the way an auditor would read it.
- Drafted responses to the mock audit findings, and readiness support as you close them.
What you supply: your current SOPs, the study list, staff CVs and training records, vendor contracts, and investigators who review and adopt every document.
The limit: trial conduct, participant safety and research judgments remain your investigators'. IHS does not monitor trials or make protocol decisions. Sponsor audits and FDA inspections are hosted by your site, and your site, not IHS, deals with the sponsor and FDA.
What to have ready
Each item ties to ICH E6(R3) (final version adopted 6 January 2025, as issued by FDA in September 2025) or to 21 CFR Part 312 as cited.
- A list of current and planned studies, marked against the guideline's scope (E6(R3), Scope), showing which are interventional trials of investigational products headed to regulators and which are other interventional trials where only the Principles may help.
- Your current SOPs, so they can be read against the guideline's call for risk-based, proportionate methods.
- A delegation log that shows who was handed which trial tasks. E6(R3) 2.3.3 scales the documentation to how significant the task is, and notes that delegation records may not be needed where the work is part of ordinary clinical practice.
- A way to show investigator oversight of delegated work. E6(R3) 2.3.1 leaves final responsibility with the investigator and sets the level of oversight by the nature of the delegated work and the risk to participants and data.
- Written, documented agreements with vendors that carry out trial tasks (E6(R3) 2.3.4).
- A procedure for hosting sponsor monitoring and audits, regulatory inspection and IRB/IEC review (E6(R3) 2.3.5).
- A records retention schedule that meets 21 CFR 312.62(c) for drug and biologic studies and any longer period in the sponsor agreement or other applicable requirements: records kept "for a period of 2 years following the date a marketing application is approved" for the indication, or "until 2 years after the investigation is discontinued and FDA is notified" (21 CFR 312.62(c)).
- Investigator CVs and training records that show investigators are "qualified by training and experience as appropriate experts to investigate the drug" (21 CFR 312.53(a)).
Printable version of this checklist (PDF)
How it compares
| Route | What it involves | Source |
|---|---|---|
| Internal E6(R3) quality system | The site builds SOPs and records to the guideline; sponsor audits and regulatory inspection are the external checks the guideline expects sites to permit | E6(R3) 2.3.5 |
| SASI Clinical Research Site Accreditation | A site accreditation program that SASI says grew out of the Alliance for Clinical Research Excellence and Safety (ACRES). Protocol Version 5.0 describes a path from a self-assessment against SASI's standard through a surveyor's review of the site's documents, online and on-site assessment, a findings report and corrective actions, ending with review by SASI's Site Accreditation Council (document opened October 3, 2026) | SASI Accreditation Protocol v5.0 |
| IAOCR GCSA site certification | A site certification that IAOCR presents as a global quality standard for clinical trial sites, centered on business operations (IAOCR's own description, page opened October 3, 2026) | IAOCR |
IHS's reading (October 2026): an accreditation or certification is a separate decision from building the quality system, and a site that pursues one still needs the SOPs and records that E6(R3) describes. For sites whose studies go through an IRB, see also IRB registration and Federalwide Assurance alignment.
What it costs
E6(R3) and 21 CFR Part 312 describe what a site works to, and the pages we reviewed state no fee for compliance. SASI's protocol says a non-refundable application and commitment fee applies and gives no figure (document opened October 3, 2026). The IAOCR services page we opened gives no fee figure either (page opened October 3, 2026). Verify current fees with SASI and IAOCR. IHS scopes each engagement after a free introductory call.
What this is not
- This page is not legal advice, and IHS's reading of how guidance and regulation interact is not a regulatory determination for your studies.
- IHS does not guarantee the outcome of a sponsor audit, an accreditation decision or an FDA inspection.
- IHS does not monitor trials, act as an investigator, or deal with sponsors or FDA on your site's behalf.
Frequently asked questions
What is Good Clinical Practice under ICH E6(R3)?
Under ICH E6(R3), GCP is the international standard that trials with human participants are planned and run to, covering ethics, science and the quality of the work (ICH E6(R3), document opened October 3, 2026). ICH adopted the final version on 6 January 2025.
Does ICH E6(R3) apply to my site, and is it legally binding in the US?
E6(R3) is aimed at interventional trials of investigational products whose results are meant for regulators, and ICH says the Principles may also help on other interventional trials not meant to support a marketing application, as local requirements allow (document opened October 3, 2026). IHS's reading (October 2026) is that E6(R3) is guidance in the US, and the enforceable requirements for drug and biologic studies sit in FDA regulations such as 21 CFR Part 312. Your regulatory counsel should confirm how that applies to your studies.
When did FDA adopt ICH E6(R3)?
FDA lists E6(R3) Good Clinical Practice (GCP) as final guidance issued in September 2025, docket FDA-2023-D-1955 (FDA, page opened October 3, 2026). ICH had adopted the final guideline on 6 January 2025.
What SOPs does a clinical research site need under GCP?
The set depends on the studies the site runs, since E6(R3) favors a risk-based approach scaled to the trial. The sections cited on this page point to procedures for delegation, investigator oversight, service-provider agreements, and hosting monitoring, audits and inspections, plus records retention under 21 CFR 312.62(c). IHS builds the list from a crosswalk of your studies against the guideline.
What does a delegation-of-authority log need to show under E6(R3)?
Section 2.3.3 calls for a record of the people and parties the investigator has handed trial tasks to, with documentation scaled to how significant each task is. Section 2.3.1 keeps final responsibility with the investigator, who is to oversee the delegated work (document opened October 3, 2026).
How should an investigator oversee vendors and service providers under E6(R3)?
Section 2.3.4 calls for the investigator or institution to document its agreements with service providers. The oversight duty in section 2.3.1 reaches any person or party carrying out delegated activities, so the site needs both the agreement and a record of oversight (document opened October 3, 2026).
How long must a site keep records for an FDA-regulated drug or biologic study?
Under 21 CFR 312.62(c), an investigator keeps required records "for a period of 2 years following the date a marketing application is approved for the drug for the indication for which it is being investigated," or, if no application is filed or it is not approved, "until 2 years after the investigation is discontinued and FDA is notified" (eCFR). That is the Part 312 minimum for investigational drug studies. E6(R3) section 2.12.12 ties the investigator or institution's retention of essential records to the period that applicable regulatory requirements set, or until the sponsor says the records are no longer needed, whichever is longest (document opened October 3, 2026). Device studies, sponsor agreements and other rules may therefore set a different or longer period, so confirm the period with the sponsor's contract and your counsel.
How do I prepare my site for a sponsor audit or an FDA inspection?
E6(R3) section 2.3.5 expects the investigator or institution to give access to the sponsor's monitors and auditors, to regulatory inspectors and, where requirements apply, to IRB/IEC reviewers (document opened October 3, 2026). Preparation means the delegation, training, vendor and retention records above are current and retrievable. IHS runs a mock sponsor audit against them. Your site hosts the real audit or inspection.
Should an independent research site pursue site accreditation (SASI, GCSA) or just build a GCP quality system?
They are different things. SASI Clinical Research Site Accreditation and IAOCR's GCSA certification are external programs with their own assessment steps, while an E6(R3) quality system is what the site runs day to day and what sponsors audit. The choice depends on what your sponsors and your own strategy call for; IHS builds the quality system either way and does not grant or predict any accreditation.
